Goldman Sachs
AVXL icon

Goldman Sachs’s Anavex Life Sciences AVXL Stock Holding History

Goldman Sachs’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-157,400
Closed -$894K – 6020
2024
Q3 		$894K Buy
+157,400
New +$908K ﹤0.01% 4715
2023
Q2 		– Sell
-252,500
Closed -$2.16M – 5742
2023
Q1 		$2.16M Buy
252,500
+11,000
+5% +$110K ﹤0.01% 3796
2022
Q4 		$2.24M Buy
+241,500
New +$2.58M ﹤0.01% 3853

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Goldman Sachs's AVXL Position: Q2 2026 in Review

Goldman Sachs increased its Anavex Life Sciences (AVXL) stake by 11% in Q2 2026, buying an estimated $255K and bringing the position to 890,634 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4562.

Goldman Sachs first reported a position in AVXL in Q1 2016 and has held it in 33 quarters since. The position peaked at $6.6M in Q4 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Goldman Sachs held 890,634 shares of Anavex Life Sciences worth $2.31M as of Q2 2026.
  • Goldman Sachs bought 86,199 Anavex Life Sciences shares in Q2 2026, an estimated $255K.
  • Anavex Life Sciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4562 holding.
  • Goldman Sachs first reported a position in Anavex Life Sciences in Q1 2016 and has held it in 33 quarters since.
  • Goldman Sachs's Anavex Life Sciences position peaked at $6.6M in Q4 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.